- Report
- April 2026
- 144 Pages
Global
From €3633EUR$3,999USD£3,136GBP
- Report
- January 2026
- 181 Pages
Global
From €3220EUR$3,545USD£2,780GBP
€3578EUR$3,939USD£3,089GBP
- Report
- February 2026
- 250 Pages
Global
From €4079EUR$4,490USD£3,521GBP
- Report
- February 2026
- 250 Pages
Global
From €4079EUR$4,490USD£3,521GBP
- Report
- December 2025
- 142 Pages
Global
From €4406EUR$4,850USD£3,804GBP
- Report
- April 2025
- 200 Pages
Global
From €2262EUR$2,490USD£1,953GBP
- Report
- September 2023
- 180 Pages
Global
From €5405EUR$5,950USD£4,666GBP
- Report
- June 2024
- 200 Pages
Global
From €7222EUR$7,950USD£6,235GBP
- Report
- June 2022
- 320 Pages
Global
From €12627EUR$13,900USD£10,901GBP
- Report
- January 2024
- 206 Pages
Global
From €4042EUR$4,450USD£3,490GBP
- Report
- June 2023
- 280 Pages
Global
From €2271EUR$2,500USD£1,961GBP

Choroidal Neovascularization (CNV) is a condition in which abnormal blood vessels grow beneath the retina in the eye. It is a major cause of vision loss in age-related macular degeneration (AMD). Optical treatments for CNV include laser photocoagulation, photodynamic therapy, and anti-VEGF injections. Laser photocoagulation is used to destroy the abnormal blood vessels and prevent further vision loss. Photodynamic therapy uses a light-activated drug to destroy the abnormal vessels. Anti-VEGF injections are used to block the growth of new vessels and reduce fluid leakage.
The CNV market is highly competitive, with a number of companies offering treatments and products. These include Novartis, Regeneron, Allergan, Roche, Bayer, and Santen Pharmaceuticals. Show Less Read more